Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyalogy is a line of advanced cosmeceutical products developed by the Japanese company Forlle'd, centered on a patented low-molecular-weight hyaluronic acid (LMWHA). Utilizing a proprietary fermentation and ionization process, the hyaluronic acid molecules are reduced to a size of 5 to 11 nanometers, which is significantly smaller than the 3,000+ nanometers of standard hyaluronic acid. This nanotechnology allows the molecules to cross the skin barrier and reach the dermal layers without the need for invasive injections. Once in the dermis, the LMWHA interacts with CD44 receptors to stimulate fibroblast activity, promoting the synthesis of endogenous collagen and elastin while providing intense hydration and antioxidant protection. The product line is primarily used for skin rejuvenation, anti-aging, and improving skin barrier function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hyalogy.